samedan logo

 
 
spacer
home > ebr > summer 2019 > the adc jigsaw
PUBLICATIONS
European Biopharmaceutical Review

The ADC Jigsaw

The decades-old war on cancer has yet to be won. While progress has been significant in many indications, mortality rates for some of the most difficult to treat solid tumour types have not improved substantially since the 1970s. For oesophagus and lung cancer, 10-year survival statistics have shown an increase of less than 10%, and pancreatic cancer has shown no improvement at all (1). Furthermore, even in cancers such as melanoma, breast, and uterine where survival rates have improved, more efficacious treatments with fewer debilitating side effects are needed.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Jenny Thirlway leads Iksuda’s ADC programmes, including the preclinical demonstration of Iksuda’s proprietary PermaLink® conjugation chemistry, the exemplification of novel toxin platforms, and the evaluation of partnered antibodies/ alternative scaffolds, focused on the development of a proofof- concept stage ADC portfolio. Jenny has a post-doctoral background in biochemistry and significant experience in the development of biologics, including antibody-based therapeutics and biosimilars.
spacer
Dr Jenny Thirlway
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Datwyler to Double Capacity at its Indian Facility

Datwyler is increasing capacity for all three of its production standards in Pune, India. The expansion will nearly double capacity and add 400 jobs.
More info >>

White Papers

What You Need To Know About Thermal Shipping Technologies

Temptime Corporation

This paper presents highlights from a thermal performance study conducted by Modality Solutions LLC. The study examined the performance of five shipping technologies commonly used by specialty pharmacies to transport high-value refrigerated specialty medicines against an industry accepted temperature profile standard.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement